319 results
Page 3 of 16
8-K
EX-99.1
zjpjlmj i4y
11 Aug 23
Regulation FD Disclosure
4:08pm
8-K
EX-99.1
u1o wj57173gjk0t
11 Aug 23
Kineta Reports Second Quarter 2023 Financial Results and Provides Corporate Update
4:03pm
8-K
EX-99.1
52gfvidbso
29 Jun 23
Kineta to Receive $5 Million Milestone Payment from Merck
7:01am
8-K
EX-99.1
qr0sfj
28 Jun 23
Departure of Directors or Certain Officers
7:00am
424B3
zeefb70j29
12 Jun 23
Prospectus supplement
5:01pm
8-K
EX-99.1
ig7ll0mpj1911opmh
9 Jun 23
Submission of Matters to a Vote of Security Holders
9:00am
8-K
EX-99.1
jdsiueehfe1
24 May 23
Regulation FD Disclosure
9:30am
8-K
EX-99.1
suul4g
23 May 23
Kineta to Present at Jefferies Healthcare Conference
9:30am
8-K
EX-99.1
4mye4
11 May 23
Kineta Reports First Quarter 2023 Financial Results and Provides Corporate Update
5:20pm
8-K
EX-4.1
qhzuukhs v48
21 Apr 23
Kineta, Inc. Announces $6 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
5:16pm
8-K
EX-4.3
xxypeu00 qfsodpcai
21 Apr 23
Kineta, Inc. Announces $6 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
5:16pm
8-K
EX-10.1
mxwq6ind
21 Apr 23
Kineta, Inc. Announces $6 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
5:16pm
8-K
EX-99.1
0qou 26xfn8z
21 Apr 23
Kineta, Inc. Announces $6 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
5:16pm
8-K
EX-4.2
7eun527b1kz4zk3xmwa7
21 Apr 23
Kineta, Inc. Announces $6 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
5:16pm
424B5
eg1gn9nnh2hitvb
21 Apr 23
Prospectus supplement for primary offering
5:14pm
8-K
EX-99.1
8ko37 gd5c1
17 Apr 23
Kineta Unveils New VISTA Biomarker Data and KVA12123 Phase 1/2 Clinical Trial Update at AACR Annual Meeting 2023
11:09am